Výsledky vyhledávání

Chinese Version of the Baylor Profound Mental Status Examination: A Brief Staging Measure for Patients with Severe Alzheimer’s Disease

Autor: R. S. Doody, P. J. Massman, X. Fu, X. Wang, M. Ke, Yang Lü, W. Yu, J. Zhang, T. Luo

Publikováno v: The Journal of Prevention of Alzheimer's Disease. :1-6

BACKGROUND: A specialized instrument for assessing the cognition of patients with severe Alzheimer’s disease (AD) is needed in China. Objectives: To validate the Chinese version of the Baylor Profound Mental Status Examination (BPMSE-Ch). Design: T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d11c802300a5ac2878f0daafb0fca76
https://doi.org/10.14283/jpad.2020.72

Zobrazit plný text záznamu

Is Alzheimer's Disease Drug Development Broken? What Must Be Improved?

Autor: R S, Doody

Publikováno v: The journal of prevention of Alzheimer's disease. 1(1)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::837ff947e8d07800cc3577442a230c0f
https://pubmed.ncbi.nlm.nih.gov/29261215

Zobrazit plný text záznamu

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe

Autor: H H, Feldman, R S, Doody, M, Kivipelto, D L, Sparks, D D, Waters, R W, Jones, E, Schwam, R, Schindler, J, Hey-Hadavi, D A, DeMicco, A, Breazna, P P, Zolnouni

Publikováno v: Neurology. 74:956-964

BACKGROUND: There is some evidence that statins may have a protective and symptomatic benefit in Alzheimer disease (AD). The LEADe study is a randomized controlled trial (RCT) evaluating the efficacy and safety of atorvastatin in patients with mild t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a4567ed6ec2232c71e3dd945d1b53dd
https://doi.org/10.1212/wnl.0b013e3181d6476a

Zobrazit plný text záznamu

Donepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial

Autor: R S, Doody, S H, Ferris, S, Salloway, Y, Sun, R, Goldman, W E, Watkins, Y, Xu, A K, Murthy

Publikováno v: Neurology. 72:1555-1561

Treatment of mild cognitive impairment (MCI) with cholinesterase inhibitors may improve symptoms.In this multicenter, randomized, placebo-controlled trial, subjects with MCI entered a 3-week placebo run-in period followed by 48 weeks of double-blind

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::949a00bb79c550bc16e315d1dc03a39c
https://doi.org/10.1212/01.wnl.0000344650.95823.03

Zobrazit plný text záznamu

Effects of blood pressure on neuropsychological functioning in Alzheimer's disease

Autor: R. N. Davis, P. J. Massman, R. S. Doody

Publikováno v: Archives of Clinical Neuropsychology. 18:19-32

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0f0cd5c0d6d47ae60c9e014315b19dac
https://doi.org/10.1093/arclin/18.1.19

Zobrazit plný text záznamu

Alien limb sign

Autor: P A, Hanna, R S, Doody

Publikováno v: Advances in neurology. 82

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bdefc79dc08fb531b407d0075ef86b61
https://pubmed.ncbi.nlm.nih.gov/10624477

Zobrazit plný text záznamu

Therapeutic standards in Alzheimer disease

Autor: R S, Doody

Publikováno v: Alzheimer disease and associated disorders. 13

Donepezil is an effective, well-tolerated, and easily administered symptomatic treatment for mild-to-moderate Alzheimer disease (AD). Data from Phase III clinical trials have demonstrated that donepezil improves cognition, global function, and activi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0547f6dcf2ab59767e846074a2f2a8d9
https://pubmed.ncbi.nlm.nih.gov/10622675

Zobrazit plný text záznamu

Efficacy of donepezil in Alzheimer's disease: fact or artifact?

Autor: W. A. van Gool, S. L. Rogers, L. T. Friedhoff, M. R. Farlow, R. S. Doody, R. Mohs

Publikováno v: Neurology. 52(1)

To the Editor: From their study of donepezil, Rogers et al. conclude that this drug is “efficacious in treating symptoms of memory and cognitive loss in patients with mild to moderately severe AD.”1 The following characteristics of their methodol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa2788355cda15cb628041f0c6e17d4f
https://pubmed.ncbi.nlm.nih.gov/9443470

Zobrazit plný text záznamu

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group

Autor: S L, Rogers, R S, Doody, R C, Mohs, L T, Friedhoff

Publikováno v: Archives of internal medicine. 158(9)

Donepezil hydrochloride (Aricept) is a selective acetylcholinesterase inhibitor developed for the treatment of Alzheimer disease. This phase 3 study was 1 of 2 pivotal trials undertaken to establish the efficacy and safety of using donepezil in patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f9600f504c99f21934cc6f2ef79f7717
https://pubmed.ncbi.nlm.nih.gov/9588426

Zobrazit plný text záznamu

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

Autor: S L, Rogers, M R, Farlow, R S, Doody, R, Mohs, L T, Friedhoff

Publikováno v: Neurology. 50(1)

The efficacy and safety of donepezil as a treatment for patients with mild to moderate Alzheimer's disease (AD) was investigated in a multicenter, double-blind study. Patients were randomly assigned to treatment with placebo (n = 162), 5 mg/d donepez

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0876a97d77f4fa0356482cfd32be74e8
https://pubmed.ncbi.nlm.nih.gov/9921890

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání